Home > Insider Trading > Filing (0001181431-13-019348)

Filing Details

Accession Number:: 0001181431-13-019348
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-03-28 16:37:32
Reporting Period:: 2013-03-26

Filing Date:: 2013-03-28
Accepted Time:: 2013-03-28 16:37:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1520041	Saints Capital Granite, L.p.	C/O Saints Capital Services, Llc 475 Sansome Street, Suite 1850 San Francisco CA 94111	No	No	Yes	No
1521306	Saints Capital Granite, Llc	475 Sansome Street Suite 1850 San Francisco CA 94111	No	No	Yes	No
1572509	Obp (Bermuda) Iii - Holdings Llc	475 Sansome Street Suite 1850 San Francisco CA 94111	No	No	Yes	No
1572511	Mrna - Holdings Llc	475 Sansome Street Suite 1850 San Francisco CA 94111	No	No	Yes	No
1572512	Obp Iii - Holdings Llc	475 Sansome Street Suite 1850 San Francisco CA 94111	No	No	Yes	No
1572513	Obp (Adjunct) Iii - Holdings Llc	475 Sansome Street Suite 1850 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-03-26	66,474	$14.00	102,176	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2013-03-26	621,262	$0.00	723,438	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2013-03-26	924,523	$0.00	1,647,961	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2013-03-26	424,014	$0.00	2,071,975	No	4	C	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Funds
No	4	C	Indirect	By Funds
No	4	C	Indirect	By Funds
No	4	C	Indirect	By Funds

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Convertible Preferred Stock	Disposition	2013-03-26	2,000,000	$0.00	621,262	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2013-03-26	3,028,374	$0.00	924,523	$0.00
Common Stock	Series G-2 Convertible Preferred Stock	Disposition	2013-03-26	1,827,508	$0.00	424,014	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

This share number consists of (i) 628 shares of Common Stock owned directly by mRNA - Holdings LLC ("mRNA"), (ii) 5,589 shares of Common Stock owned directly by OBP (Adjunct) III - Holdings LLC ("OBP (A) III"), (iii) 7,513 shares of Common Stock owned directly by OBP (Bermuda) III - Holdings LLC ("OBP (B) III") and (iv) 52,744 shares of Common Stock owned directly by OBP III - Holdings LLC ("OBP III", and together with mRNA, OBP (A) III, and OBP (B) III, the "Funds").
Saints Capital Granite, L.P. ("Saints LP") is a member of each of the Funds and has voting and investment control with respect to the securities owned directly by the Funds. Saints Capital Granite, LLC ("Saints LLC") is the general partner of Saints LP. Saints LP disclaims beneficial ownership of the securities owned directly by the Funds, except to the extent of any pecuniary interest therein, if any, by virtue of its membership interest in the Funds. Saints LLC disclaims beneficial ownership of the securities owned directly by the Funds, except to the extent of any pecuniary interest therein, if any, by virtue of its general partner interests in Saints LP.
The Series D Convertible Preferred Stock has no expiration date and each share of Series D Convertible Preferred Stock converted automatically into approximately 0.31063 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
This share number consists of (i) 5,851 shares of Common Stock underlying shares of Series D Convertible Preferred Stock owned directly by mRNA, (ii) 46,594 shares of Common Stock underlying shares of Series D Convertible Preferred Stock owned directly by OBP (A) III, (iii) 70,955 shares of Common Stock underlying shares of Series D Convertible Preferred Stock owned directly by OBP (B) III and (iv) 497,862 shares of Common Stock underlying shares of Series D Convertible Preferred Stock owned directly by OBP III.
The Series E Convertible Preferred Stock has no expiration date and each share of Series E Convertible Preferred Stock converted automatically into approximately 0.30529 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
This share number consists of (i) 8,699 shares of Common Stock underlying shares of Series E Convertible Preferred Stock owned directly by mRNA, (ii) 78,319 shares of Common Stock underlying shares of Series E Convertible Preferred Stock owned directly by OBP (A) III, (iii) 104,472 shares of Common Stock underlying shares of Series E Convertible Preferred Stock owned directly by OBP (B) III and (iv) 733,033 shares of Common Stock underlying shares of Series E Convertible Preferred Stock owned directly by OBP III.
The Series G-2 Convertible Preferred Stock has no expiration date and each share of Series G-2 Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
This share number consists of (i) 4,041 shares of Common Stock underlying shares of Series G-2 Convertible Preferred Stock owned directly by mRNA, (ii) 35,064 shares of Common Stock underlying shares of Series G-2 Convertible Preferred Stock owned directly by OBP (A) III, (iii) 47,939 shares of Common Stock underlying shares of Series G-2 Convertible Preferred Stock owned directly by OBP (B) III and (iv) 336,970 shares of Common Stock underlying shares of Series G-2 Convertible Preferred Stock owned directly by OBP III.